Bausch Health Companies financials
$5.80+0.52%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.85B | $2.52B | $2.80B | $2.68B | $2.53B | $2.26B | $2.56B | $2.51B | $2.40B | $2.15B | $2.41B | $2.24B |
| Gross profit | $2.08B | $1.79B | $2.00B | $1.93B | $1.77B | $1.56B | $1.83B | $1.81B | $1.68B | $1.51B | $1.70B | $1.61B |
| Gross margin | 72.9% | 70.8% | 71.5% | 72.0% | 69.8% | 69.0% | 71.6% | 72.3% | 70.1% | 70.3% | 70.7% | 72.2% |
| Operating income | $740.0M | -$950.0M | $616.0M | $619.0M | $444.0M | $276.0M | $805.0M | $318.0M | $409.0M | $281.0M | $362.0M | $14.0M |
| Net income | $258.0M | -$1.42B | -$112.0M | $179.0M | $148.0M | -$58.0M | $93.0M | -$85.0M | $10.0M | -$64.0M | -$39.0M | -$378.0M |
| Net margin | 9.0% | −56.4% | −4.0% | 6.7% | 5.8% | −2.6% | 3.6% | −3.4% | 0.4% | −3.0% | −1.6% | −16.9% |
| Diluted EPS | $0.68 | $-3.82 | $-0.29 | $0.48 | $0.40 | $-0.16 | $0.25 | $-0.23 | $0.03 | $-0.17 | $-0.11 | $-1.03 |
| EBITDA | $1.03B | $784.0M | $1.15B | $943.0M | $782.0M | $582.0M | $1.22B | $641.0M | $724.0M | $634.0M | $475.0M | $735.0M |
| Operating cash flow | $670.0M | $230.0M | $495.0M | $405.0M | $289.0M | $211.0M | $601.0M | $405.0M | $380.0M | $211.0M | $390.0M | $282.0M |
| Free cash flow | $593.0M | $121.0M | $403.0M | $314.0M | $190.0M | $96.0M | $495.0M | $334.0M | $302.0M | $129.0M | $292.0M | $240.0M |
| Diluted shares | 378.1M | 372.8M | 381.8M | 375.5M | 373.1M | 369.6M | 366.6M | 368.4M | 370.2M | 366.8M | 363.8M | 365.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.82B | $1.30B | $1.31B | $1.31B | $1.73B | $1.13B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $20.76B | $20.80B | $20.84B | $21.04B | $21.74B | $21.51B |
| Total assets | $24.79B | $24.50B | $26.37B | $26.82B | $27.27B | $26.42B |
| Total liabilities | $25.60B | $25.58B | $25.99B | $26.47B | $27.12B | $26.66B |
| Shareholders' equity | -$802.0M | -$1.08B | $377.0M | $356.0M | $147.0M | -$240.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology